This article is more than 5 years old. Information may no longer be current.

Akreos aspheric IOL receives FDA approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch & Lomb announced in a press release that it has received U.S. Food and Drug Administration approval of the Akreos Advanced Optics aspheric IOL.

The Akreos AO IOL is a one-piece, foldable, acrylic IOL with a four-haptic design and aspheric optics, according to the release. The lens is implanted with the single-use AI-28 inserter, which enables single-handed insertion through a standard phaco incision.

The company plans to have the lens available on the market later this month, the release said.

"I have been treating patients with the Akreos AO Lens for more than a year and a half in Canada, and the single-piece four-haptic design allows for consistent postop centration," Rosa Braga-Mele, MD, FRCSC, said in the release.